Phase 3 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study information and are willing to sign a written consent form and follow the study schedule and procedures
- Women between 18 and 70 years of age (inclusive)
- People with a laboratory-confirmed diagnosis of breast cancer that cannot be surgically removed, has spread locally, or has spread to other parts of the body, and whose cancer tests negative for estrogen receptor (ER), progesterone receptor (PR), and HER-2 (commonly called triple-negative breast cancer)
- People who have not previously received systemic drug treatment (other than hormone therapy) for advanced breast cancer, OR people who did receive taxane-based chemotherapy before or after surgery, as long as the cancer came back or spread at least 12 months after that treatment ended
- People whose general physical functioning is rated 0 or 1 on a standard medical activity scale, meaning they are fully active or have only minor limitations in physical activity
- People with a life expectancy of at least 12 weeks
- People who have at least one tumour that can be measured on a scan according to standard criteria (confirm with trial site for specific details about which lesions qualify)
Who may not be able to join:
- People who have previously been treated with certain immune-boosting or immune-checkpoint drugs (such as CTLA-4, PD-1, PD-L1, or LAG3 inhibitors, or CD137 agonists), or with drugs that target blood vessel growth (anti-VEGF therapies)
- People who have brain or spinal cord metastases that are not controlled or are causing symptoms
- People who have had another active cancer within the past 5 years, unless that cancer was treated locally and is considered fully cured
- People with poorly controlled high blood pressure (readings of 140 mmHg or higher for the top number, and/or 90 mmHg or higher for the bottom number)
- People with a history of a hypertensive crisis or a condition called hypertensive encephalopathy (a severe complication of very high blood pressure)
- People who have had an abnormal passage or hole in the abdomen, between the throat and oesophagus, in the digestive system, or an internal abdominal infection within the past 6 months
- People who still have side effects from previous cancer treatments that have not reduced to a mild level or resolved, based on standard medical grading criteria
- People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled
- People who have previously received a stem cell transplant from a donor or an organ transplant
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jiong Wu, professor, Fudan University
Phone: +86 13810452270
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC); Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.